---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Second-generation h1 antihistamines"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Second-generation h1 antihistamines. Topics: First-line standard-dose second-generation H1-antihistamine: 2026 international guideline, Updosing up to four-fold as second-line treatment: 2026 international guideline, First-generation H1-antihistamines and combinations of antihistamines: 2026 international guideline, Leukotriene receptor antagonists as add-on therapy: 2026 international guideline, and 7 further topics. 11 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/second-generation-h1-antihistamines"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Second-generation h1 antihistamines

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Second-generation H1 Antihistamines

<a id="topic-2.2.2.1.1-1"></a>

### First-line standard-dose second-generation H1-antihistamine: 2026 international guideline

> “We recommend a 2nd generation H1‐antihistamine as first‐line treatment for all types of urticaria.”
> “Most, but not all 2nd generation H1‐antihistamines have been tested specifically in urticaria, and evidence supports the use of bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine”
> “We recommend the use of a standard‐dosed modern 2nd generation H1‐antihistamines as the first‐line symptomatic treatment for urticaria. However, no recommendation can be made on which to choose because, to date, well‐designed clinical trials directly comparing the efficacy and safety of all modern 2nd generation H1‐antihistamines in urticaria are largely lacking.”
> “We suggest 2nd generation H1‐antihistamines to be taken regularly for the treatment of patients with chronic spontaneous urticaria.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-2"></a>

### Updosing up to four-fold as second-line treatment: 2026 international guideline

> “We recommend updosing of a 2nd generation H1‐antihistamine up to 4‐fold in patients with chronic urticaria unresponsive to a standard‐dosed 2nd generation H1‐antihistamines as second‐line treatment before other treatments are considered.”
> “We recommend against using higher than 4‐fold standard dosed H1‐antihistamines in chronic urticaria”
> “Patients need to be informed that 2nd generation H1‐antihistamine updosing is off‐label and higher than fourfold is not recommended as it has not been tested.”
> “For updosing, also the time of onset needs to be considered, for example, for treatment with an antihistamine, further improvement cannot be expected after 1–2 weeks of treatment as receptor saturation is complete after 1 week.”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-3"></a>

### First-generation H1-antihistamines and combinations of antihistamines: 2026 international guideline

> “The older 1st generation H1‐antihistamines have pronounced anticholinergic and sedative effects and many interactions with alcohol and other drugs such as analgesics, hypnotics, sedatives, and mood elevating drugs, have been described.”
> “we recommend against their use for the routine management of CU as first‐line agents”
> “We suggest against using different H1‐antihistamines at the same time (against an updosing of a single H1‐antihistamine if not legally restricted in country)”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-4"></a>

### Leukotriene receptor antagonists as add-on therapy: 2026 international guideline

> “In general, the level of evidence for the efficacy of leukotriene receptor antagonists in urticaria is low, but the most so far for montelukast.”
> “A recent, systematic review and meta‐analysis found that adding leukotriene receptor antagonists to H1 antihistamines provides modest reductions in urticaria activity without significantly increasing overall adverse events, though the risk of neuropsychiatric effects remains uncertain”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.1-5"></a>

### Draft 2026 AAAAI/ACAAI Joint Task Force guideline: review invitation and scope

> “ACAAI President Cherie Zachary, MD, FACAAI invites you to review the draft of Chronic Urticaria Guidelines: 2026 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations.”
> “The 2026 guideline focuses in greater depth on CU in children and adults, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), angioedema associated with CU, disease monitoring, comorbidities, health disparities, special populations, patient and caregiver experience, and sequencing of conventional and advanced therapies.”

Source: [ACAAI JTF chronic urticaria guideline announcement (2026)](https://college.acaai.org/new-chronic-urticaria-practice-parameter-update-puts-greater-emphasis-on-core-concepts-patient-centered-implementation/)

<a id="topic-2.2.2.1.1-6"></a>

### Dose-response network meta-analysis of 211 randomized trials for the Joint Task Force guideline update

> “As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria.”
> “Random effects network and dose–response meta-analyses addressed urticaria activity, angioedema activity, urticaria-related quality of life, and harms including sedation.”
> “A total of 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, and fexofenadine are among the most effective in overall improvement. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also effective in improving urticaria-related quality of life.”
> “Dose–response meta-analyses suggest that there may be diminishing additional benefits beyond standard dosing (Fig 3, A; RD to improve by a minimal important difference with double dose: RD 8 more per 100 participants [95% CI, 7 to 9 more]; quadruple dose: RD 16 more [95% CI, 11 to 20 more]).”
> “Second-generation agents may result in a greater reduction compared to first-generation agents (MD −2.51 [95% CrI, −5.01 to −0.02]; RD 10 more [95% CrI, 0 to 19 more]; low certainty).”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-7"></a>

### Montelukast and H2 blocker adjuncts to a second-generation antihistamine: urticaria activity

> “Adding montelukast likely results in a greater reduction compared to a second-generation agent alone (MD −3.28 [95% CrI, −5.87 to −0.68]; RD 11 more [95% CrI, 3 to 17 more]; moderate certainty). The impact of the addition of an H2 blocker compared to a second-generation agent alone is very uncertain (MD −3.83 [95% CrI, −10.41 to 2.77]; very low certainty).”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-8"></a>

### Sedation by agent and dose

> “Sedation risk likely increases with higher doses, with first-generation agents like diphenhydramine among the most sedating, while sedation risk differs among second-generation agents.”
> “Cetirizine (OR = 2.71 [95% CrI, 1.80 to 4.07]; RD 5 more [95% CrI, 3 to 9 more]), levocetirizine (OR = 3.20 [95% CrI, 1.69 to 6.06]; RD 7 more [95% CrI, 2 to 14 more]), and rupatadine (OR = 2.05 [95% CrI, 1.10 to 3.81]; RD 3 more [95% CrI, 0 to 8 more]) are among the intermediate sedating.”
> “High-certainty evidence demonstrates that bepotastine (OR = 0.53 [95% CrI, 0.22 to 1.31]; RD 2 fewer [95% CrI, 3 fewer to 1 more]) and loratadine (OR = 1.04 [95% CrI, 0.62 to 1.72]; RD 0 more [95% CrI, 1 fewer to 2 more]) are not more sedating than placebo”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-9"></a>

### Implications for guidelines and payers of diminishing benefit beyond a standard dose

> “Our findings show a diminishing benefit beyond a standard dose”
> “This contrasts with current guidelines that strongly recommend increasing to 4-fold dosing for almost all patients with disease that does not respond to a standard dose.”
> “These findings underscore the need to update guidelines, refine the definition of antihistamine refractoriness, and consider alternatives to dose escalation, such as the timely initiation of biologics and systemic immunomodulators, especially when most systemic therapy trials did not require participants’ disease to be refractory to 4-fold dosing.”
> “Payors should support and enable these decisions rather than create barriers such as rigid criteria, cumbersome preauthorization, or exceptional access processes.”

Source: [Chu et al. (2026)](https://doi.org/10.1016/j.jaci.2026.09.030)

<a id="topic-2.2.2.1.1-10"></a>

### Response to updosing among standard-dose nonresponders: systematic review and meta-analysis

> “The objective of this systematic review is to explore and analyse available data to provide clinical evidence for the efficacy of antihistamine updosing.”
> “We identified 1042 articles and 15 articles were included in the final evaluation. We performed two meta-analyses, one that included studies that analysed treatment response among groups receiving different antihistamine dosages vs. placebo, and another that analysed antihistamine updosing in those patients who did not respond to standard dosages.”
> “Only five articles obtained a high quality level score. We did not find significant differences in response rates or number of weals in those patients who received a standard dosage vs. a high dosage.”
> “The estimated relative risk for improvement by increasing the antihistamine dosage was 2·27 [95% confidence interval (CI) 1·68-3·06]; however, there was significant heterogeneity. The proportion of nonrespondent patients with CSU who responded to antihistamine updosing was 63·2% (95% CI 57-69·6).”

Source: [Guillén-Aguinaga et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27237730/)

<a id="topic-2.2.2.1.1-11"></a>

### Uncontrolled disease at Month 24 on non-sedating and updosed antihistamines: AWARE real-world study, sponsored by the omalizumab manufacturer

> “AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global, prospective, non-interventional study in the real-world setting, sponsored by the manufacturer of omalizumab.”
> “Overall, 23.2% (n/N = 26/112) patients on non-sedating H1 -antihistamines (nsAH) and 41.9% (n/N = 44/105) patients on up-dosed nsAH had uncontrolled CSU (UCT <12) at Month 24. In omalizumab-treated patients, 27.1% (n/N = 78/288) had uncontrolled CSU at Month 24.”

Source: [Maurer et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32735720/)

Additional sources: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
